The Cutting Edge of Diagnosis and Treatment in Rheumatologic Diseases

Dear Colleagues,

As rheumatologists, we need to be acutely aware of the importance of early and accurate diagnosis in rheumatologic diseases. Many rheumatologic diseases are chronic, debilitating conditions that can significantly impact a patient's quality of life if left untreated or improperly managed. Therefore, it is crucial to explore the critical aspects of diagnosis and treatment in rheumatologic diseases to improve patient outcomes and quality of life.

One of the key challenges in rheumatologic diseases is the limitations of current diagnostic approaches. Despite significant advances in diagnostic imaging and laboratory testing, rheumatologic diseases can be difficult to diagnose due to their complex and multifactorial nature. Novel biomarkers, imaging techniques and clinical assessment tools can help overcome these limitations and improve diagnosis accuracy. The use of these tools can also lead to an earlier detection of disease, allowing for earlier treatment and improved outcomes.

In addition, targeted therapies have revolutionized the management of rheumatologic diseases by providing high-efficacy treatments. Biologics and JAK inhibitors, in particular, have shown significant promise in treating rheumatoid arthritis, psoriatic arthritis and other rheumatologic diseases. However, their use raises concerns about potential adverse events and their impact on long-term survival outcomes. Therefore, it is critical to explore the latest advances and challenges in targeted therapies for rheumatologic diseases, including potential adverse events and their impact on long-term survival outcomes.

This Special Issue brings together cutting-edge research, reviews and perspectives from experts in the field to comprehensively examine the current challenges and advances related to diagnosis and treatment in rheumatologic diseases. By providing insights into the most effective treatment approaches, potential adverse events and their impact on patient outcomes, this Special Issue can inform clinical decision making, and ultimately improve patient outcomes and quality of life.

Dr. Ji-hyoun Kang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• rheumatologic disease
• diagnosis
• JAK inhibitors
• targeted therapies
• biologics
• biomarkers
• adverse events
• safety issue
• drug survival rate
• risk groups
• long-term treatment outcomes
• COVID-19
• drug–drug antibodies